Anti-tumor application of orally administrated FIP-fve on antitumor application

From the paper

Abstract

The anti-tumor effect of FIP-fve, an immunomodulatory protein derived from Flammulina velutipes, was well demonstrated. Oral administration of FIP-fve (200 mg protein/mouse) every other day significantly increased the survival of BNL 1MEA.7R.1 hepatoma-bearing mice and inhibits the growth of hepatoma (p < 0.05). In naive mice, orally administered FIP-fve enhanced the production of TNF-alpha and nitric oxide by peritoneal macrophages, whether in the presence or absence of LPS. In addition, peritoneal macrophages obtained from FIP-fve-fed naive mice had increased cytotoxicity against hepatoma cells (p < 0.05). In hepatoma-bearing mice, oral administration of FIP-fve significantly increased the serum levels of tumor-specific IgG (p < 0.05). Splenocytes obtained from FIP-fve-fed hepatoma-bearing mice had increased tumor-specific proliferation and upregulated production of IFN-gamma and TNF-alpha (p < 0.05), as well as enhanced cytotoxicity against hepatoma cells (p < 0.05).